Our Leadership
Management Committee Executive Group
Adrian van den Hoven
Chair, IGBA
Director General, Medicines for Europe
Adrian van den Hoven has been director general of Medicines for Europe since September 2013.
In his role he focuses on stimulating competition in off-patent medicine markets, fostering access to medicine, reducing medicine shortages and addressing major health crises, supporting policy measures for sustainable pricing, promoting efficient regulatory standards, and developing a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value-added medicines industries.
He is also member, and former president, of the European Medicines Verification Organization (EMVO) board for the implementation of serialization against falsified medicines, the vice-chair of the International Generic and Biosimilar medicines Association (IGBA) and a member of the joint industry advisory council of the Health Emergency and Response Authority (HERA).
Shinichiro Hirose, Ph.D.
Vice-Chair, IGBA 2024
Director of International Affairs, Japan Generic Medicines Association (JGA)
Shinichiro Hirose is the director of international affairs at the Japan Generic Medicines Association (JGA), a member association of the IGBA. In this position, he is responsible for coordinating activities on international affairs and other expert committees of the association. He is a member of IGBA management committee, and other standing committees. He is also engaged in ICH project, taking a role as ICH coordinator for IGBA. Before joining JGA, he worked for pharmaceutical industry over 30 years, and has experiences in research, business development, and marketing for international markets. He holds the Ph.D. degree in pharmaceutical sciences from the university of Tokyo, Japan.
David R. Gaugh, R. Ph.
Immediate Past Chair IGBA
Interim CEO, Association for Accessible Medicines (AAM)
David Gaugh has over 25 years of leadership experience in the Healthcare and Pharmaceutical business. He has been employed by AAM (formerly GPhA) since February 2012 as the Senior Vice President for Sciences and Regulatory Affairs, where he is responsible for the professional liaison functions between member companies, agencies of the U.S. Government and Legislative bodies for all responsible areas. Prior to joining AAM, David was Vice President and General Manager of Bedford Laboratories, a Division of Ben Venue Laboratories and a wholly owned subsidiary of Boehringer Ingelheim. Prior to Bedford Laboratories, David was Senior Director, Pharmacy Contracting and Marketing at VHA/ Novation (now Vizient). And prior to VHA/Novation, David was System Director of Pharmacy for St. Luke’s Health-System, a tertiary- care hospital in Kansas City, MO. David is a registered Pharmacist and has been engaged in several board-level pharmacy-related activities.
